Inactive Instrument

Highlights Regulus Therapeutics Inc Nasdaq

Equities

US75915K1016

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in Its Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Mar. 12	CI
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	Jan. 02	CI
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Nov. 02	CI
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	23-09-13	CI
Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	23-06-27	CI
Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	23-05-16	CI
Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	23-04-12	CI
Sanofi Terminates Second Amended and Restated Collaboration and License Agreement with Regulus Therapeutics Inc	23-01-06	CI
Regulus Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	22-11-02	CI
Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	22-09-12	CI
Earnings Flash (RGLS) REGULUS THERAPEUTICS Posts Q2 Loss $-0.50	22-08-11	MT
Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Reverse Split: 1 of 10	22-06-28	FA
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	22-06-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Regulus Therapeutics Inc Nasdaq

Equities

US75915K1016

Highlights

Filters